Literature DB >> 21393607

Avastin's uncertain future in breast cancer treatment.

Renee Twombly.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21393607     DOI: 10.1093/jnci/djr088

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  5 in total

1.  Public voices in pharmaceutical deliberations: negotiating "clinical benefit" in the FDA's Avastin Hearing.

Authors:  Christa B Teston; S Scott Graham; Raquel Baldwinson; Andria Li; Jessamyn Swift
Journal:  J Med Humanit       Date:  2014-06

2.  Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow-derived cells.

Authors:  Hanna S Kuznetsov; Timothy Marsh; Beth A Markens; Zafira Castaño; April Greene-Colozzi; Samantha A Hay; Victoria E Brown; Andrea L Richardson; Sabina Signoretti; Elisabeth M Battinelli; Sandra S McAllister
Journal:  Cancer Discov       Date:  2012-08-15       Impact factor: 39.397

Review 3.  Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer.

Authors:  Robert S Kerbel
Journal:  J Mammary Gland Biol Neoplasia       Date:  2012-09-26       Impact factor: 2.673

Review 4.  Watching tumours gasp and die with MRI: the promise of hyperpolarised 13C MR spectroscopic imaging.

Authors:  K Brindle
Journal:  Br J Radiol       Date:  2012-04-11       Impact factor: 3.039

Review 5.  Fibroblasts as architects of cancer pathogenesis.

Authors:  Timothy Marsh; Kristian Pietras; Sandra S McAllister
Journal:  Biochim Biophys Acta       Date:  2012-10-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.